3-Ethyl-7-[(5-thiocarbamoyl-1H-indole-2-carbonyl)-amino]-heptanoic acid tert-butyl ester | 169463-99-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-Ethyl-7-[(5-thiocarbamoyl-1H-indole-2-carbonyl)-amino]-heptanoic acid tert-butyl ester
• 英文别名: tert-butyl 7-[(5-carbamothioyl-1H-indole-2-carbonyl)amino]-3-ethylheptanoate
• CAS: 169463-99-4
• 化学式: C₂₃H₃₃N₃O₃S
• 分子量: 431.599
• InChiKey: GYKVREVNXLFEPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  30
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  129
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-Ethyl-7-[(5-thiocarbamoyl-1H-indole-2-carbonyl)-amino]-heptanoic acid tert-butyl ester 在 ammonium acetate 、 potassium carbonate 、 三氟乙酸 、 碘甲烷 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 7-[(5-Carbamimidoyl-1H-indole-2-carbonyl)-amino]-3-ethyl-heptanoic acid
  参考文献：
  名称：

  Use of Conformationally Restricted Benzamidines as Arginine Surrogates in the Design of Platelet GPIIb-IIIa Receptor Antagonists

  摘要：

  The use of 5,6-bicyclic amidines as arginine surrogates in the design of a novel class of potent platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa) antagonists is described. The additional conformational restriction offered by the bicyclic nucleus results in 20-400-fold increases in potency compared to the freely flexible, acyclic benzamidine counterpart. The design, synthesis, structure-activity relationships (SAR), and in vitro activity of this novel class of GPIIb-IIIa antagonists are presented.

  DOI：

  10.1021/jm970020k
• 作为产物：
  描述：

  二乙基膦酰基乙酸叔丁酯 在 palladium on activated charcoal 吡啶 、 4-二甲氨基吡啶 、 TEA 、 硫化氢 、 氢气 、 sodium hydride 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 4.0h， 生成 3-Ethyl-7-[(5-thiocarbamoyl-1H-indole-2-carbonyl)-amino]-heptanoic acid tert-butyl ester
  参考文献：
  名称：

  Use of Conformationally Restricted Benzamidines as Arginine Surrogates in the Design of Platelet GPIIb-IIIa Receptor Antagonists

  摘要：

  The use of 5,6-bicyclic amidines as arginine surrogates in the design of a novel class of potent platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa) antagonists is described. The additional conformational restriction offered by the bicyclic nucleus results in 20-400-fold increases in potency compared to the freely flexible, acyclic benzamidine counterpart. The design, synthesis, structure-activity relationships (SAR), and in vitro activity of this novel class of GPIIb-IIIa antagonists are presented.

  DOI：

  10.1021/jm970020k